Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.

ABSTRACT: Immunotherapy is revolutionizing cancer treatment and has shown success in particular for tumors with a high mutational load. These effects have been linked to neoantigens derived from patient-specific mutations. To expand efficacious immunotherapy approaches to the vast majority of tumor types and patient populations carrying only a few mutations and maybe not a single presented neoepitope, it is necessary to expand the target space to non-mutated cancer-associated antigens. Mass spectrometry enables the direct and unbiased discovery and selection of tumor-specific human leukocyte antigen (HLA) peptides that can be used to define targets for immunotherapy. Combining these targets into a warehouse allows for multi-target therapy and accelerated clinical application. For precise personaliza

SUBMITTER: Fritsche J 

PROVIDER: S-EPMC6032917 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature